Can your own fat cells rebuild a damaged knee?

NCT ID NCT05526898

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial is testing whether injecting a person's own fat tissue, processed with a special device, can reduce pain and improve function in people with knee osteoarthritis. Participants will receive either the fat tissue injection or a standard corticosteroid injection. The study will compare changes in knee pain and function over time to see if this approach offers a better treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous microsized adipose tissue processed with the SyntrFuge system, compared to a corticosteroid injection (standard care)
What this could lead to
If effective, this could offer a new, minimally invasive treatment option for knee osteoarthritis that may reduce pain and improve joint function without surgery.
What could go wrong
This is an early-stage trial, and the treatment may not prove more effective than standard care. Risks include injection-related discomfort, infection, or variable results depending on individual response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2027

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Subjects aged of 35-80 years old * Patients with knee osteoarthritis grade II, III, and IV Kellgren-Lawrence * Chronic knee pain or symptoms for at least 3 months * BMI between 20 and 34.9 * Willing and able to read and sign the informed consent and other study materials * Written informed consent has been obtained prior to any study-related procedures * Written Authorization for Use and Release of Health and Research Study Information has been signed * Subjects are ambulatory * Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study * Females of childbearing potential must have a negative urine pregnancy test result and not be lactating * Subject is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the Investigator's opinion, exposes the Subject to an unacceptable risk by study participation Exclusion Criteria: * Subjects with previous traumatic lesion (tibial fracture, osteothomy) of the knee * Subjects with osteonecrosis * Subjects with meniscal surgery in the previous 6 weeks * Subjects with gout, hyperlipidemia * Subjects without decisional capacity * Subjects with inflammatory arthritis * Subjects with active infection * Subjects with any uncontrolled systemic disease * Subjects with a history of severe allergic/anaphylactic reactions or multiple allergies * Subjects planning to become pregnant, are pregnant, or are breast-feeding * Subjects with history or current evidence of drug or alcohol abuse within 36 months prior to screening visit * Subjects who have active autoimmune disease * Subjects who have coagulation disorders * Subjects who have received any other therapy, which, in the opinion of the investigator, could interfere with safety or efficacy evaluations * Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study * Subjects with any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study * Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 7 days pre- to 3 days post injection. A wash out period of 7 days is allowed * Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit. * No intra-articular injection of corticosteroids within the last 24 weeks * No intra-articular injection of any other cellular therapy within the last 24 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Irvine Site 1

    Irvine, California, 92618, United States

  • Irvine Site 2

    Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.